Develop a candidate subunit vaccine for Powassan Virus and West Nile virus adjuvanted with Alhydroxiquim-II

NIH RePORTER · NIH · N01 · $274,999 · view on reporter.nih.gov ↗

Abstract

Powassan virus is a flavivirus that can be transmitted by at least six tick species within the Ixodes and Dermacentor families, and can cause severe encephalitis and neurologic sequelae. It is the only tick-borne flavivirus endemic in North America. West Nile virus, also a flavivirus, is mostly transmitted by Culex mosquitoes, has a broad host range, and can cause encephalitis or meningitis associated with lengthy patient recovery. No human vaccine is currently available for either disease. The contractor will generate novel subunit vaccines, applying the lessons learned from their previous work with other flavivirus vaccines, and formulate it with Alhydroxiquim-II, an adjuvant that is used in the Covaxin COVID vaccine.

Key facts

NIH application ID
10678270
Project number
272201800049C-P00010-9999-2
Recipient
VIROVAX LLC
Principal Investigator
SUNIL DAVID
Activity code
N01
Funding institute
NIH
Fiscal year
2022
Award amount
$274,999
Award type
Project period
2018-09-30 → 2023-09-29